These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6097458)

  • 1. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects.
    Witte PU; Irmisch R; Hajdú P; Metzger H
    Eur J Clin Pharmacol; 1984; 27(5):577-81. PubMed ID: 6097458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of renal function on the pharmacokinetics of ramipril (HOE 498).
    Debusmann ER; Pujadas JO; Lahn W; Irmisch R; Jané F; Kuan TS; Mora J; Walter U; Eckert HG; Hajdú P
    Am J Cardiol; 1987 Apr; 59(10):70D-78D. PubMed ID: 3034037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ramipril in the elderly.
    Meyer BH; Müller FO; Badian M; Eckert HG; Hajdú P; Irmisch R; Schmidt D
    Am J Cardiol; 1987 Apr; 59(10):33D-37D. PubMed ID: 3034031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.
    Bussien JP; Nussberger J; Porchet M; Waeber B; Brunner HR; Perisic M; Tansey MJ; Bomm M; Hajdu P
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):63-9. PubMed ID: 2987705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of ramipril in renal failure.
    Aurell M; Delin K; Herlitz H; Ljungman S; Witte PU; Irmisch R
    Am J Cardiol; 1987 Apr; 59(10):65D-69D. PubMed ID: 3034036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients.
    Gilchrist WJ; Beard K; Manhem P; Thomas EM; Robertson JI; Ball SG
    Am J Cardiol; 1987 Apr; 59(10):28D-32D. PubMed ID: 3034029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man.
    Manhem PJ; Ball SG; Morton JJ; Murray GD; Leckie BJ; Fraser R; Robertson JI
    Br J Clin Pharmacol; 1985 Jul; 20(1):27-35. PubMed ID: 2992562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).
    Gerckens U; Grube E; Mengden T; Sigel H; Wagner WL; Lahn T; Irmisch R; Metzger H
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S49-51. PubMed ID: 2474102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
    Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
    Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
    Witte PU; Metzger H; Eckert HG; Irmisch R
    Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man.
    Eckert HG; Badian MJ; Gantz D; Kellner HM; Volz M
    Arzneimittelforschung; 1984; 34(10B):1435-47. PubMed ID: 6097271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
    Böhm RO; van Baak MA; Rahn KH
    Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288.
    Gohlke P; Schölkens B; Henning R; Urbach H; Unger T
    J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S32-6. PubMed ID: 2483426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
    Schölkens BA; Becker RH; Kaiser J
    Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
    Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
    Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors.
    Gohlke P; Urbach H; Schölkens B; Unger T
    J Pharmacol Exp Ther; 1989 May; 249(2):609-16. PubMed ID: 2542535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite.
    Eckert HG; Münscher G; Oekonomopulos R; Strecker H; Urbach H; Wissmann H
    Arzneimittelforschung; 1985; 35(8):1251-6. PubMed ID: 3000393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.
    Ocón-Pujadas J; Debusmann ER; Jane F; Lahn W; Irmisch R; Mora J; Grötsch H
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S45-8. PubMed ID: 2474101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
    Becker RH; Schölkens BA; Metzger M; Schulze KJ
    Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
    Stumpe KO; Overlack A; Kolloch R; Schatz J; Witte PU; Pahnke K
    Klin Wochenschr; 1986 Jun; 64(12):558-62. PubMed ID: 3016405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.